Eargo 8 vs Otofonix Groove

The Eargo 8 is a premium-priced OTC hearing aid ($2,399) that earns a B grade with a SoundScore of 3.3/5 in our lab testing. This invisible-in-ear device represents Eargo's 2025 flagship offering, featuring a rechargeable design that sits completely within the ear canal. In our testing, the Eargo 8 showed mixed performance across key metrics. Speech clarity in quiet environments is a relative strength, scoring 0.27 points above the OTC category average. Own-voice comfort also performs well, measuring 0.69 points above average at 3.2/5—a solid result that suggests reduced occlusion effects during conversation. However, speech understanding in noisy environments scored 1.2/5, which is both low in absolute terms and 0.27 points below the category average. The most significant limitation we measured was music streaming, which scored 0.0/5—nearly 2 points below the OTC average. This makes the Eargo 8 unsuitable for users who prioritize streaming audio quality. Feedback handling is strong in absolute terms at 4.2/5, though slightly below the category average. At its premium price point, the Eargo 8 faces stiff competition. Several devices in our database deliver comparable or better sound performance at lower prices, including alternatives from Eargo's own lineup. The Eargo 8 is best suited for users who prioritize invisible cosmetics and own-voice comfort over streaming capability and value, and who primarily need help hearing speech in quieter settings.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE ranks #38 of 39 devices in the prescription hearing aid category, placing it in the bottom 5% of its class. In our testing, the Groove demonstrated excellent feedback handling at 5.0/5, scoring 0.28 points above the category average. This represents a genuine strength, with the device maintaining stability during our standardized challenge motions. However, speech performance was significantly limited, with speech in quiet scoring 1.0/5 (2.40 points below the category average of 3.40) and speech in noise also at 1.0/5 (1.11 points below average). Music streaming was not functional in our tests, scoring 0.0/5 against a category average of 2.76. Own-voice comfort also fell well below typical prescription hearing aid performance at 0.4/5, which is 2.30 points below the category average. At this price point, several lower-cost alternatives delivered stronger overall performance in our testing. Consumers seeking value in the prescription category may want to explore other options, though those requiring robust feedback control in a rechargeable BTE format may find the Groove's stability noteworthy despite its other limitations.